Abstract
Background
The aim of the study was to compare the proposed spinal anesthetic effect of ifenprodil, an a1 adrenergic receptor antagonist, with that of the long-acting local anesthetic bupivacaine.
Methods
After intrathecally injecting the rats with five different doses of each drug, the dose-response curves of ifenprodil and bupivacaine were constructed to obtain the 50% effective dose (ED50). The spinal blockades of motor function and nociception of ifenprodil were compared with that of bupivacaine.
Results
We showed that either ifenprodil or bupivacaine produced spinal blockades of motor function and nociception dose-dependently. On the ED50 basis, the potency of ifenprodil (0.42(0.38–0.46) μmol; 0.40(0.36–0.44) μmol) was equal (p > 0.05) to that of bupivacaine (0.38(0.36–0.40) μmol; 0.35(0.32–0.38) μmol) in motor function and nociception, respectively. At the equianesthetic doses (ED25, ED50, and ED75), duration produced by ifenprodil was greater than that produced by bupivacaine in motor function and nociception (p < 0.05 for the differences). Furthermore, both ifenprodil and bupivacaine showed longer duration of sensory blockade than that of motor blockade (p < 0.05 for the differences).
Conclusions
The resulting data demonstrated that ifenprodil produces a dose-dependent local anesthetic effect in spinal anesthesia. Ifenprodil shows a more sensory-selective duration of action over motor block, whereas the duration of anesthesia is significantly longer with ifenprodil than with bupivacaine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Young AR, Bouloy M, Boussard JF, Edvinsson L, MacKenzie ET. Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels. J Cereb Blood Flow Metab 1981;1:117–28.
Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, et al. Separation of alpha 1 adrenergic and N-methyl-d-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 1991;34:3085–90.
Carron C, Jullien A, Bucher B. Synthesis and pharmacological properties of a series of 2-piperidino alkanol derivatives. Arzneimittelforschung 1971;21:1992–8.
Young AR, Barry DI, MacKenzie ET, Robert JP. Cerebro-circulatory effects of so-called ‘vasodilators’ in the anaesthetised rat. Eur Neurol 1983;22:142–53.
Marquis P, Lecasble M, Passa P. Quality of life of patient with peripheral arterial obliterative disease treated with ifenprodil tartrate. Results of an ARTEMIS study. Drugs 1998;56(Suppl. 3):37–48.
Williams K. Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 1993;44:851–9.
Gallagher MJ, Huang H, Pritchett DB, Lynch DR. Interactions between ifenprodil and the NR2B subunit of the N-methyl-d-aspartate receptor. J Biol Chem 1996;271:9603–11.
Williams K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets 2001;2:285–98.
Wang XM, Bausch SB. Effects of distinct classes of N-methyl-d-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro: suppression by NR2B-selective antagonists. Neuropharmacology 2004;47:1008–20.
Chizh BA, Reissmuller E, Schlutz H, Scheede M, Haase G, Englberger W. Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil. Neuropharmacology 2001;40:212–20.
Kupila J, Karkkainen O, Laukkanen V, Hakkinen M, Kautiainen H, Tiihonen J, et al. [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: a whole-hemisphere autoradiography study. Psychiatry Res 2015;231:197–201.
Hashimoto K, London ED. Further characterization of [3H]ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 1993;236:159–63.
Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED. Further characterization of [3H]ifenprodil binding in rat brain. Eur J Pharmacol 1994;266:67–77.
Hashimoto K, London ED. Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 1995;273:307–10.
Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology 2006;31: 516–24.
Tanahashi S, Iida H, Oda A, Osawa Y, Uchida M, Dohi S. Effects of ifenprodil on voltage-gated tetrodotoxin-resistant Na+ channels in rat sensory neurons. Eur J Anaesthesiol 2007;24:782–8.
Church J, Fletcher EJ, Baxter K, MacDonald JF. Blockade by ifenprodil of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones: comparison with N-methyl-d-aspartate receptor antagonist actions. Br J Pharmacol 1994;113:499–507.
Bath CP, Farrell LN, Gilmore J, Ward MA, Hicks CA, O’Neill MJ, et al. The effects of ifenprodil and eliprodil on voltage-dependent Ca2+ channels and in gerbil global cerebral ischaemia. Eur J Pharmacol 1996;299:103–12.
Delaney AJ, Power JM, Sah P. Ifenprodil reduces excitatory synaptic transmission by blocking presynaptic P/Q type calcium channels. J Neurophysiol 2012;107:1571–5.
Brittain MK, Brustovetsky T, Brittain JM, Khanna R, Cummins TR, Brustovetsky N. Ifenprodil, a NR2B-selective antagonist of NMDA receptor, inhibits reverse Na+/Ca2+ exchanger in neurons. Neuropharmacology 2012;63:974–82.
Sheets MF, Hanck DA. Molecular action of lidocaine on the voltage sensors of sodium channels. J Gen Physiol 2003;121:163–75.
Scholz A. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 2002;89:52–61.
Mizusawa H, Yamane M, Sakai K. Pharmacodynamics of 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propanol (Ifenprodil). (3) Effects on the autonomic, peripheral and central nervous systems. Nihon Yakurigaku Zasshi 1976;72:185–99.
Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK. A Comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to Bupivacaine. J Anaesthesiol Clin Pharmacol 2011;27:339–43.
Punj J, Khan RM. Spinal anaesthesia for pelvic surgery: low concentrations of lignocaine and bupivacaine are effective with less adverse events. Middle East J Anaesthesiol 2013;22:71–7.
Vandermeersch E, Kick O, Mollmann M, de Gouw N, Van Aken H. CSE — the combination of spinal and epidural anesthesia. Reg Anaesth 1991;14:108–12.
Zhang W, Shi CX, Gu XP, Ma ZL, Zhu W. Ifenprodil induced antinociception and decreased the expression of NR2B subunits in the dorsal horn after chronic dorsal root ganglia compression in rats. Anesth Analg 2009;108:1015–20.
Sudoh Y, Desai SP, Haderer AE, Sudoh S, Gerner P, Anthony DC, et al. Neurologic and histopathologic evaluation after high-volume intrathecal amitriptyline. Reg Anesth Pain Med 2004;29:434–40.
Chen YW, Huang KL, Liu SY, Tzeng JI, Chu KS, Lin MT, et al. Intrathecal tri-cyclic antidepressants produce spinal anesthesia. Pain 2004;112:106–12.
Leung YM, Chu CC, Kuo CS, Chen YW, Wang JJ. Nisoxetine blocks sodium currents and elicits spinal anesthesia in rats. Pharmacol Rep 2013;65: 350–7.
Hung CH, Chu CC, Chen YC, Chen YW, Li ZY, Wang JJ. Spinal anesthesia with diphenhydramine and pheniramine in rats. Eur J Pharmacol 2011;673:20–4.
Hung CH, Chu CC, Chen YC, Liu KS, Chen YW, Wang JJ. Cutaneous analgesia and systemic toxicity of carbetapentane and caramiphen in rats. Reg Anesth Pain Med 2012;37:34–9.
Chen YW, Chu CC, Chen YC, Wang JJ, Hung CH. The local anesthetic effect of memantine on infiltrative cutaneous analgesia in the rat. Anesth Analg 2011;113:191–5.
Ma YY, Yu P, Guo CY, Cui CL. Effects of ifenprodil on morphine-induced conditioned place preference and spatial learning and memory in rats. Neurochem Res 2011;36:383–91.
Bhattacharya P, Pandey AK, Paul S, Patnaik R. Combination therapy of ifenprodil with piroxicam may be an effective therapeutic intervention in cerebral stroke: a hypothesis. Med Hypotheses 2012;79:516–8.
Karbon EW, Patch RJ, Pontecorvo MJ, Ferkany JW. Ifenprodil potently interacts with [3H](+)-3-PPP-labeled sigma binding sites in guinea pig brain membranes. Eur J Pharmacol 1990;176:247–8.
McCool BA, Lovinger DM. Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. Neuropharmacology 1995;34:621–9.
Fozzard HA, Lee PJ, Lipkind GM. Mechanism of local anesthetic drug action on voltage-gated sodium channels. Curr Pharm Des 2005;11:2671–86.
Scholz A, Kuboyama N, Hempelmann G, Vogel W. Complex blockade of TTX-resistant Na+ currents by lidocaine and bupivacaine reduce firing frequency in DRG neurons. J Neurophysiol 1998;79:1746–54.
Chaplan SR, Malmberg AB, Yaksh TL. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 1997;280:829–38.
Laurido C, Pelissier T, Perez H, Flores F, Hernandez A. Effect of ketamine on spinal cord nociceptive transmission in normal and monoarthritic rats. Neuroreport 2001;12:1551–4.
Suzuki R, Matthews EA, Dickenson AH. Comparison of the effects of MK-801, ketamine and memantine on responses ofspinal dorsal horn neurones in a rat model of mononeuropathy. Pain 2001;91:101–9.
Sakurada T, Wako K, Sugiyama A, Sakurada C, Tan-No K, Kisara K. Involvement of spinal NMDA receptors in capsaicin-induced nociception. Pharmacol Biochem Behav 1998;59:339–45.
Rondon ES, Vieira AS, Valadao CA, Parada CA. The improvement of the anti-hyperalgesic effect of ketamine and of its isomers by the administration of ifenprodil. Eur J Pharmacol 2010;647:84–9.
Cameron AE, Cross FW. Pain, mobility after inguinal herniorrhaphy: ineffectiveness of subcutaneous bupivacaine. Br J Surg 1985;72:68–9.
Hannibal K, Galatius H, Hansen A, Obel E, Ejlersen E. Preoperative wound infiltration with bupivacaine reduces early and late opioid requirement after hysterectomy. Anesth Analg 1996;83:376–81.
Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979;51:285–7.
Khan MA, Gerner P, Kuo Wang G. Amitriptyline for prolonged cutaneous analgesia in the rat. Anesthesiology 2002;96:109–16.
Fanelli A, Ghisi D, Allegri M. Is spinal anaesthesia a suitable technique for ultrashort outpatient procedures? Acta Biomed 2013;84:76–80.
Camponovo C, Wulf H, Ghisi D, Fanelli A, Riva T, Cristina D, et al. Intrathecal 1% 2-chloroprocaine vs. 0.5% bupivacaine in ambulatory surgery: a prospective, observer-blinded, randomised, controlled trial. Acta Anaesthesiol Scand 2014;58:560–6.
Camponovo C. Spinal 1% 2-Chloroprocaine versus general anesthesia for ultrashort outpatient procedures: a retrospective analysis. Acta Biomed 2014;85:265–8.
Chazot PL. The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 2004;11:389–96.
Childers Jr. WE, Baudy RB. N-methyl-d-aspartate antagonists and neuropathic pain: the search for relief. J Med Chem 2007;50:2557–62.
Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA. Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl) 2005;179:85–98.
Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006;6:68–74.
Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther 1988;247:1211–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, YW., Chiu, CC., Wang, JN. et al. Ifenprodil for prolonged spinal blockades of motor function and nociception in rats. Pharmacol. Rep 68, 357–362 (2016). https://doi.org/10.1016/j.pharep.2015.09.011
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2015.09.011